drugset / Trial / NCT01809132

Efficacy Study of Anakinra, Pentoxifylline, and Zinc Compared to Methylprednisolone in Severe Acute Alcoholic Hepatitis

NCT01809132 ↗

RandomizedParallel-groupTriple-blindTreatment

Summary

This study will compare two different treatments of acute alcoholic hepatitis. The current standard of care is treatment with corticosteroids (methylprednisolone). This will be compared to treatment with anakinra, pentoxifylline, plus zinc sulfate. The participants will be treated and followed for 6 months and the two treatment groups will be compared for differences in death rates and laboratory tests that measure liver and gut function.

Timeline

Start
2013-09
Primary completion
2018-10
Completion
2018-10

Outcome

Missed primary endpoint

registry analysis (superiority test); Anakinra & Pentoxifylline & Zinc Sulfate vs Methylprednisolone; p = .30; Log Rank NCT01809132 ↗

paper Kaplan-Meier survival estimate at 180 days was 67.9% in COMB and 56% in PRED (HR = 0.69; p = 0.3001). PMID 35340032 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Anakinra Protein / enzyme biologic 100 mg Subcutaneous
Comparator Methylprednisolone Other / unclassified 32 mg Oral
Subject Pentoxifylline Small molecule 400 mg Oral
Subject Zinc Sulfate Unknown 220 mg Oral

Indications